Prognostic and Predictive Biomarkers in Ovarian Cancers
ConditionOvarian Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorGustave Roussy, Cancer Campus, Grand Paris
About this trial
The investigators therefore propose to conduct a biological study of prospectively collected patient tumour samples, ascites, blood and other residual samples (feces, urine, vaginal smear) throughout the disease course where markers (at diagnosis and their change with treatment) will be correlated to outcome in order to investigate how genetic diversity in OC prior to treatment and adaptation following treatment contribute to chemotherapy resistance. In addition freshly collected ascitic samples (and tumour samples) will be subjected to ex vivo DNA repair functional assays and isolated in primary culture (and established as xenografts) for target validation experiments.
Eligibility criteria
Qualifiers
New patient with a diagnosis of OC, or
Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center presenting with progressive disease, and consenting to CT guided biopsy of relapsed disease, or
Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center scheduled for surgery for relapsed disease.
Signed informed consent
Disqualifiers
Patients who do not fit the inclusion criteria and those who refuse an antitumoral treatment;
Coagulation abnormalities that contra-indicates the biopsy
Trial design
Treatments tested in this trial
- Blood sample
Treatment groups
350 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov